<< Back
Molecular MD:
OHSU researchers Brian Druker and Michael Heinrich launched this company to diagnose and monitor treatment of specific cancers. The major product of Molecular MD is a quantitative assay to monitor response to treatment for chronic myelogenous leukemia.
ID Biopharma:
This company is a spinoff of an earlier OHSU startup, Virogenomics, Inc. ID Biopharma focuses on infectious diseases, with the goal of facilitating the development of diagnostics, treatments, and vaccines targeting various diseases.
Yecuris, Inc.:
Founded by OHSU professor Markus Grompe, this company addresses the problem of analyzing drug toxicity. Large numbers of human liver cells are needed to test whether drugs become toxic when metabolized by the liver. Yecuris will supply this market by producing human liver cells in mice.
Cylerus:
This is the latest startup from OHSU researcher Stephen Hanson. He previously founded Revitus to develop pharmaceuticals to prevent heart attacks. Hanson's newest venture aims to improve function of artificial blood vessels by developing technology for local drug delivery to the vessels.
Portland Bioscience, Inc.:
Aiming to determine individual genotypes for diagnostic and treatment purposes, Portland Bioscience has collaborated with OHSU researcher Cheryl Maslen. Maslen's research group has studied a mutation in a cell surface adhesion protein, CRELD1, as a potential indicator of metastatic activity in cancers. Portland Bioscience plans to develop commercial assays for the CRELD1 mutation, among other personalized diagnostic tools.
|